ORKA insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Quinlan Paul T General Counsel · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Warrant (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 61996 · The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025. | 2026-11-20 | 2026-11-20 | 9,000 shares/units | SEC 4 | Follow |
| Quinlan Paul T General Counsel · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 29995 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.56 to $96.64, inclusive. | 2026-11-20 | 2026-11-20 | ≈ $19,320.00 200 shares/units | SEC 4 | Follow |
| Quinlan Paul T General Counsel · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 30195 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.52 to $96.30, inclusive. | 2026-11-20 | 2026-11-20 | ≈ $239,986.00 2,500 shares/units | SEC 4 | Follow |
| Quinlan Paul T General Counsel · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 32695 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.46 to $95.22, inclusive. | 2026-11-20 | 2026-11-20 | ≈ $284,319.60 3,000 shares/units | SEC 4 | Follow |
| Quinlan Paul T General Counsel · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 35695 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.40 to $94.38, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. | 2026-11-20 | 2026-11-20 | ≈ $310,360.05 3,300 shares/units | SEC 4 | Follow |
| Quinlan Paul T General Counsel · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 38995 | 2026-11-20 | 2026-11-20 | 9,000 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Warrant (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 157992 · The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. | 2026-11-16 | 2026-11-16 | 3,500 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 186563 · The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. | 2026-11-16 | 2026-11-16 | 3,500 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 31771 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.48 to $106.20, inclusive. | 2026-11-16 | 2026-11-16 | ≈ $52,928.00 500 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 32271 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.26 to $103.46, inclusive. | 2026-11-16 | 2026-11-16 | ≈ $20,672.00 200 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 32471 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.18 to $102.95, inclusive. | 2026-11-16 | 2026-11-16 | ≈ $30,741.00 300 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 32771 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.11 to $102.09, inclusive. | 2026-11-16 | 2026-11-16 | ≈ $192,900.92 1,900 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 34671 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.11 to $101.04, inclusive. | 2026-11-16 | 2026-11-16 | ≈ $150,718.80 1,500 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 36171 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.03 to $99.98, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. | 2026-11-16 | 2026-11-16 | ≈ $258,739.00 2,600 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 38771 | 2026-11-16 | 2026-11-16 | 3,500 shares/units | SEC 4 | Follow |
| Goncalves Joana Chief Medical Officer · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 35271 | 2026-11-16 | 2026-11-16 | 3,500 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 55417 · The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. | 2026-11-12 | 2026-11-13 | 1,458 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Stock Option (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 67834 · The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. | 2026-11-12 | 2026-11-13 | 8,542 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 14219 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. | 2026-11-12 | 2026-11-13 | ≈ $10,700.00 100 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 14319 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.82 to $106.52, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $101,716.51 958 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 15277 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.82 to $105.81, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $720,329.87 6,842 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 22119 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $104.65, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $83,295.91 799 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 22918 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.75 to $103.70, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $82,627.64 801 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 23719 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.22, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), and (6) to this Form 4. | 2026-11-12 | 2026-11-13 | ≈ $50,987.90 500 shares/units | SEC 4 | Follow |
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 24219 | 2026-11-12 | 2026-11-13 | 1,458 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.